Set-back for Biodynamics in Japan:
This article was originally published in Clinica
Following a World Health Organisation recommendation, the Japanese Ministry of Health has banned all use of human dura mater. Japan is a significant market for one manufacturer, Biodynamics, which intends to protest to the WHO. In a separate development, Biodynamics has struck a deal with Muscoloskeletal Transplant Foundation which will recover dura mater tissue in the US and pass it to Biodynamics for processing.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.